Innocan Pharma CorpCanadian Securities Exchange:INNOView on OTCQB
- LAST PRICE0.2800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.2800/ 3
- Ask / Lots0.3000/ 295
- Open / Previous Close0.0000 / 0.2800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INNO |
|---|---|---|
| 09:34 ET | 40500 | 0.28 |
| 09:38 ET | 3000 | 0.28 |
| 10:21 ET | 8000 | 0.28 |
| 12:05 ET | 4500 | 0.28 |
| 12:16 ET | 9000 | 0.275 |
| 12:18 ET | 7000 | 0.275 |
| 03:54 ET | 500 | 0.28 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Innocan Pharma Corp | 77.9M | -11.1x | --- |
Biosyent Inc | 102.3M | 16.2x | +6.22% |
1CM Inc | 117.7M | -69.0x | --- |
Spectral Medical Inc | 132.1M | -8.4x | --- |
BellRock Brands Inc | 48.9M | -0.6x | --- |
Vext Science Inc | 50.0M | 6.6x | -18.67% |
Company Information
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
Contact Information
- Headquarters
- 10 Hamenofim StreetHERZLIYA, Israel 4672561
- Phone
- ---
- Fax
- ---
Executives
- Executive Chairman of the Board
- Ron Mayron
- Chief Executive Officer, Director
- Iris Bincovich
- Executive Vice President - Business Development, Director, Founder
- Yoram Drucker
- Chief Financial Officer
- Nelson Halpern
- Chief Operating Officer
- Roni Kamhi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $77.9M |
|---|---|
Revenue (TTM) | $18.8M |
Shares Outstanding | 276.0M |
Innocan Pharma Corp does not pay a dividend. | |
Beta | 3.08 |
EPS | $-0.03 |
Book Value | $0.02 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | 4.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -27.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
